Roche Invests In Xenon’s Novel Anemia Treatment Platform
This article was originally published in The Pink Sheet Daily
Two-year licensing, equity investment deal with the Canadian drug discovery firm will explore protein modulators to treat anemia of inflammation.
You may also be interested in...
Halozyme’s Enhanze technology could be used with virtually all biologics to improve drug delivery, the company says.
CERA will have an estimated user fee date of mid February under standard review for treatment of renal anemia.
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.